Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HIV prevention
Biotech
Merck gets FDA nod to relaunch HIV trials, drops prevention plan
A path forward for Merck & Co.’s struggling HIV strategy has opened up, with the FDA releasing a nine-month clinical hold on trials of islatravir.
James Waldron
Sep 20, 2022 10:00am
Merck's HIV program suffers 13 clinical holds from FDA
Dec 14, 2021 8:45am
Merck pauses 2 more trials of backbone HIV drug over red flag
Dec 7, 2021 7:35am
J&J previews $60B future with plans to go after evasive viruses
Nov 18, 2021 2:00pm
J&J's HIV vaccine fails phase 2b, extending long wait for a jab
Aug 31, 2021 8:30am
HIV vaccine shows signs of cross-subtype protection
Sep 20, 2019 8:33am
